These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 11313888

  • 1. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
    Brodie SG, Xu X, Li C, Kuo A, Leder P, Deng CX.
    Oncogene; 2001 Mar 22; 20(12):1445-54. PubMed ID: 11313888
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
    Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB.
    Cell Growth Differ; 1995 Jun 22; 6(6):737-48. PubMed ID: 7669729
    [Abstract] [Full Text] [Related]

  • 3. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
    Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P.
    Oncogene; 1995 Jul 06; 11(1):181-90. PubMed ID: 7624126
    [Abstract] [Full Text] [Related]

  • 4. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model.
    Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM.
    Oncogene; 2000 Nov 09; 19(47):5338-47. PubMed ID: 11103935
    [Abstract] [Full Text] [Related]

  • 5. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53.
    Cui XS, Donehower LA.
    Oncogene; 2000 Dec 07; 19(52):5988-96. PubMed ID: 11146550
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
    Cancer Res; 2006 May 01; 66(9):4672-80. PubMed ID: 16651418
    [Abstract] [Full Text] [Related]

  • 8. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
    McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB.
    Oncogene; 1998 May 28; 16(21):2755-66. PubMed ID: 9652742
    [Abstract] [Full Text] [Related]

  • 9. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.
    Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, Bortner DM, Rosenberg MP, Reed SI.
    Oncogene; 2006 Nov 23; 25(55):7245-59. PubMed ID: 16751806
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ.
    Cancer Res; 2002 Apr 01; 62(7):2077-84. PubMed ID: 11929828
    [Abstract] [Full Text] [Related]

  • 11. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS.
    Exp Mol Pathol; 2001 Jun 01; 70(3):183-93. PubMed ID: 11417997
    [Abstract] [Full Text] [Related]

  • 12. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.
    Rowse GJ, Ritland SR, Gendler SJ.
    Cancer Res; 1998 Jun 15; 58(12):2675-9. PubMed ID: 9635596
    [Abstract] [Full Text] [Related]

  • 13. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53.
    Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M, Graessmann A.
    Oncogene; 2003 May 15; 22(19):2910-9. PubMed ID: 12771941
    [Abstract] [Full Text] [Related]

  • 14. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.
    Ritland SR, Rowse GJ, Chang Y, Gendler SJ.
    Cancer Res; 1997 Aug 15; 57(16):3520-5. PubMed ID: 9270023
    [Abstract] [Full Text] [Related]

  • 15. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
    Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX.
    Oncogene; 2001 Nov 08; 20(51):7514-23. PubMed ID: 11709723
    [Abstract] [Full Text] [Related]

  • 16. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
    Ridgeway AG, McMenamin J, Leder P.
    Oncogene; 2006 Jun 15; 25(25):3518-27. PubMed ID: 16434961
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG, Barbieri O, Piccini D, Noviello E, Zoppé M, Zucchi I, Frattini A, Villa A, Vezzoni P.
    Gene Ther; 1998 Mar 15; 5(3):388-93. PubMed ID: 9614559
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
    Zinser GM, Welsh J.
    Carcinogenesis; 2004 Dec 15; 25(12):2361-72. PubMed ID: 15333467
    [Abstract] [Full Text] [Related]

  • 19. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, Morazzoni P, Riva A, Smorlesi A.
    Cancer Res; 2007 Mar 01; 67(5):2022-9. PubMed ID: 17332330
    [Abstract] [Full Text] [Related]

  • 20. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
    van Rossum AG, van Bragt MP, Schuuring-Scholtes E, van der Ploeg JC, van Krieken JH, Kluin PM, Schuuring E.
    BMC Cancer; 2006 Mar 14; 6():58. PubMed ID: 16536875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.